As shown in Fig. 5B, NPnon-targeted treatment suppressed pro-inflammatory cytokines IL-6 by 73.3% when compared to arthritis control (p-value: 0.03); TNF-α by 42% p-value: 0.002; IL-17A by 70.6%, p-value: 0.05; and IFN-γ by 61.3%, p-value: 0.03) pg/mL. This evidence concerns the gene IL17A and arthritic joint disease.